Co-administration of cG250 and IL-2 or IFN-α for...

Details Co-administration of cG250 and IL-2 or IFN-α for... Co-administration of cG250 and IL-2 or IFN-α for...

2003-06-23

2009-12-15

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C514S002600

Reexamination Certificate

active

07632496

ABSTRACT:
A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN). The improved treatment method is characterized in a significantly reduced cytokine-related toxicity combined with potentiated effectiveness of anti-G250 antibody alone, resulting in a positive therapeutic response with respect to that observed with single anti-tumor agents alone.

REFERENCES:
patent: 5104652 (1992-04-01), Houghton et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5830452 (1998-11-01), Bauer et al.
patent: WO 93/18152 (1993-09-01), None
patent: WO 97/41831 (1997-11-01), None
Busken, C et al, Digestive Disease Week Abstracts and Itinerary Planner, 2003.
Vissers et al. (1999, Cancer Research 59:5554-5559).
Uemura (1999, Brittish J. of Cancer 81(4):741-746).
Bleumer et al., (Jan. 2002, European Urology Supplements, vol. 1, No. 1, pp. 112).
Pavone (2001, Cancer Immunol. lmmunother. 50:82-86).
Wiesenthal, Human Tumor Assay Journal, on-line (http://weisenthal.org/synergy1.htm, Aug. 5, 2008.
Berenbaum, Clin exp Immunol, 1997, 28:1-18.
Beck Joachim et al., “A Phase I/II trial with monoclonal antibody WX-G250 in combination with low dose interleukin-2 in metastatic renal cell carcinoma”, Proceedings of the America Association for Cancer Research Annual, vol. 43, Mar. 2002, p. 910.
Bleumer I et al., “A phase II trial with monoclonal antibody WX-G250 in advanced renal cell carcinoma”, European Urology Supplements, vol. 1, No. 1, Jan. 2002, p. 112.
Liu Zhanqi et al., “Anti-renal cell carcinoma chimeric antibody G250: Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity”, Cancer Immunology Immunotherapy, vol. 51, No. 3, May 2002, pp. 171-177.
Van Dijk J. et al., “Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts”, International Journal of Cancer, vol. 56, No. 2, 1994, pp. 262-268.
Varga Z et al., “A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients”, Folia Biologica, vol. 49, No. 2, 2003, pp. 74-77.
Bleumer Ivar et al., “A phase I/II trial with chimeric monoclonal antibody WX-G250 in combination with low-dose interleukin-2 for patients with metastatic renal cell carcinoma”, Journal of Urology, vol. 169, No. 4 Supplement, Apr. 2003, p. 261.
Hank et al., “Augmentation of Antibody Dependent Cell Mediated Cytotoxicity following in Vivo Therapy with Recombinant Interleukin 2”, Cancer Research, 50, Sep. 1, 1990, p. 5234-5239.
Uemura et al, “Effects of MAbG250 and Anti-Idiotye Antibody Based Immunotherapy in Renal Cell Carcinoma”, Biotherapy, pp. 400-403, 11 (3) : Mar. 1997.
Christianne Buskens et al., “Adenocarcinomas of the Gastro-esophageal junction: a comparative study of the gastric cardia and the esophagus with respect to cycloxygenase-2 expression”, Digestive Disease Week Abstracts and Itinerary Planner, vol. 2003, 2003, page Abstract No. 850.
Kim A. Margolin, “Interleukin-2 in the Treatment of Renal Cancer”, Seminars in Oncology, vol. 27, No. 2, Apr. 2002, pp. 194-203.
Peter F.A. Mulders et al., “The Role of Adjuvant Immunotherapy in Renal Cell Carcinoma”, Current Urology Reports, 2002, vol. 3 pp. 44-49.
Kendall A. Smith, “Lowest Dose Interleukin-2 Immunotherapy”, Blood, vol. 81, No. 6, Mar. 15, 1993, pp. 1414-1423.
Paul M. Sondel et al., “Clinical and Immunological Effects of Recombinant Interleukin 2 Given by Repetitive Weekly Cycles to Patients with Cancer”, Cancer Research 48, May 1, 1988, pp. 2561-2567.
Jeff A. Sosman et al., “Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunological Effects of Dose, Schedule, and Addition of Indomethacin”, Journal of the National Cancer Institute vol. 80, No. 18, Nov. 16, 1998, pp. 1451-1461.
R. C. Stein et al., “The clinical effects of prolonged treatment of patients with advanced cancer with lose-dose subcutaneous interleukin 2”, Br. J. Cancer 63, 1991, pp. 275-278.
J. R. Turner et al., “MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker”, Hum Pathol Jun. 1997; 28(6):740-4, PubMed Abstract.
M.L. Nasi et al., “Treatment (tx) with daily low-dose subcutaneous (sc) interleukin-2 (IL-2) followed by monoclonal antibody R24 against GD3 ganglioside in patients (pts) with metastatic melanoma (MM)”, http://www.asco.org/prof/me/html/abstracts/ms/m—1770.htm, 1997.
Joost L. M. Vissers et al., “The Renal Cell Carcinoma-associated Antigen G250 Encodes a Human Leukocyte Antigen (HLA)-A2.1-restricted Epitope Recognized by Cytotoxic T Lymphocytes”, Cancer Research 59, Nov. 1, 1999, pp. 5554-5559.

Affiliated with

Also associated with

Rating

Co-administration of cG250 and IL-2 or IFN-α for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Co-administration of cG250 and IL-2 or IFN-α for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Co-administration of cG250 and IL-2 or IFN-α for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4131873